| Vol. 13.41 – 4 November, 2021 |
| |
|
|
| The authors reported that a fasting-mimicking diet activated starvation escape pathways in TNBC cells, which could be identified and targeted by drugs. They found that metastatic TNBC patients with lower glycemia survived longer than those with higher baseline glycemia. [Cell Metabolism] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists studied the dynamical expression of endogenously labeled Hes1, a transcriptional repressor implicated in controlling cell proliferation, to understand how cell-cycle length heterogeneity was generated in estrogen receptor (ER)+ breast cancer cells. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers demonstrated that calreticulin facilitated breast cancer progression by promoting the breast cancer stem cell phenotype through Wnt/β-catenin signaling in a hypoxia-inducible factor 1 (HIF-1)–dependent manner. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators found that inhibition or knockout of endogenous, mature microRNA-3662 in TNBC cells suppressed proliferation and migration in vitro and tumor growth and metastasis in vivo. [Oncogene] |
|
|
|
| Researchers found a set of hormone-responsive lineage-specific transcription factors, FOXA1, GATA3, ERα, directly drove high expression of arylsulfatase D (ARSD) through chromatin looping in luminal subtype breast cancer cells. [Cell Death & Disease] |
|
|
|
| Researchers demonstrated that KIT was a downstream effector of TCOF1 in mediating TNBC stemness, evaluated by in vitro and in vivo assays. [British Journal of Cancer] |
|
|
|
| Investigators showed that first-in-class leukemia inhibitory factor receptor (LIFRα) inhibitor EC359 could enhance the therapeutic efficacy of histone deacetylase inhibitors (HDACi) against TNBC. [Communications Biology] |
|
|
|
| Researchers revealed that F-box and leucine-rich repeat protein 10 (FBXL10) served as a pro-metastatic factor in breast cancer via repressing the expression of E-cadherin and inducing epithelial-mesenchymal transition (EMT). [Cell Death Discovery] |
|
|
|
| Researchers showed that combination delivery of Doxorubicin (Dox) and Conferone (Conf) to MDA-MB-231 human breast cancer cells had synergistic effects, where Dox-Conf loaded micelles significantly induced tumor cell apoptosis. [Scientific Reports] |
|
|
|
| Scientists performed LC/MS metabolic profiling on separated attached and detached MDA-MB-231 cells treated with metformin and/or 2-deoxy-D-glucose and found that the metabolic profile of detached cells was closer to untreated control cells, suggesting detachment might help cells adapt to energy stress. [Scientific Reports] |
|
|
|
|
| Investigators discuss the diverse roles of MUC4 in tumor progression and metastasis, and propose that intervening in MUC4 intercellular interactions with binding partners on blood-borne aggregating cells could potentially thwart breast cancer metastatic efficiency. [Endocrine-Related Cancer] |
|
|
|
| Scientists address the mechanistic progress on how PRK-like endoplasmic reticulum kinase (PERK) acts as a multifunctional molecule to commit 17β-estradiol to inducing apoptosis in endocrine-resistant breast cancer. [Molecular Cancer Research] |
|
|
|
| The authors examine the role of immune-activating cells, including tumour-infiltrating lymphocytes, and natural killer cells, as well as immune inhibitory cells, including T regulatory cells, and myeloid-derived suppressor cells in the breast cancer tumour microenvironment. [Breast Cancer Research and Treatment] |
|
|
|
|
| Ambrx Biopharma, Inc. announced the first patient has been dosed in its global ACE-Breast-03 Phase II clinical study of ARX788, an anti-HER2 antibody drug conjugate, in patients with HER2-positive metastatic breast cancer. [Ambrx Biopharma, Inc.] |
|
|
|
|
| November 10 – 19, 2021 Virtual |
|
|
|
|
|
| University of Maryland School of Medicine – Baltimore, Maryland, United States |
|
|
|
| Georgetown University School of Medicine – Washington, District of Columbia, United States |
|
|
|
| Medical University of Vienna – Vienna, Austria |
|
|
|
| City of Hope – Los Angeles, California, United States |
|
|
|
| The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|